"Viral Matrix Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins associated with the inner surface of the lipid bilayer of the viral envelope. These proteins have been implicated in control of viral transcription and may possibly serve as the "glue" that binds the nucleocapsid to the appropriate membrane site during viral budding from the host cell.
| Descriptor ID |
D014763
|
| MeSH Number(s) |
D12.776.964.970.880.940
|
| Concept/Terms |
Viral Matrix Proteins- Viral Matrix Proteins
- Matrix Proteins, Viral
- Proteins, Viral Matrix
- Membrane Proteins, Viral
- Viral M Proteins
- M Proteins, Viral
- Proteins, Viral M
- Viral Membrane Proteins
- Proteins, Viral Membrane
|
Below are MeSH descriptors whose meaning is more general than "Viral Matrix Proteins".
Below are MeSH descriptors whose meaning is more specific than "Viral Matrix Proteins".
This graph shows the total number of publications written about "Viral Matrix Proteins" by people in this website by year, and whether "Viral Matrix Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 2 | 1 | 3 |
| 2003 | 3 | 0 | 3 |
| 2004 | 2 | 3 | 5 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 0 | 3 | 3 |
| 2021 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Matrix Proteins" by people in Profiles.
-
Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations. Sci Adv. 2025 Sep 12; 11(37):eadx3505.
-
In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (Mpro) Inhibitors. Molecules. 2021 Apr 05; 26(7).
-
Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy. 2019 02; 21(2):212-223.
-
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
-
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
-
Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses. Antiviral Res. 2017 05; 141:62-72.
-
Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector. Clin Vaccine Immunol. 2017 Jan; 24(1).
-
EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. Methods Mol Biol. 2017; 1532:255-265.
-
Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. Vaccine. 2016 Apr 12; 34(17):1993-9.
-
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System. J Vis Exp. 2015 Oct 05; (104).